OBJECTIVES: More elderly patients (>80 years of age) are being referred for aortic valve replacement (AVR) with or without CABG. Current risk stratification models may not accurately predict the preoperative risk in these patients. We sought to determine which perioperative variables were relevant in determining short-term (30-day to in-hospital) outcomes in our intuition's series of consecutive AVR and AVR+CABG surgeries. We constructed a novel variable, patient-prosthesis mismatch (PPM) in the presence of diminished functional status (NYHA) classification, and studied its role as a predictor of mortality risk.
INTRODUCTION
Aortic valve disease affects 5.2 million Americans, particularly the elderly [1] . This number will rise in the coming decades, as the number of Americans 65 years of age and older will increase from 38.7 million to 88.5 million in 2050 [2] . Replacement of the native aortic valve (AVR) with a mechanical or bioprosthetic valve remains the optimum treatment for patients [3] . The majority of patients undergoing AVR are 65 years of age or older, but the number of patients over age the 80 of years is increasing.
Without proper replacement of the native aortic valve, untreated aortic stenosis (AS) will eventually lead to death. Patients with severe AS can expect an average survival of 3 years after the onset of symptoms. Many patients are not referred or referred too late for AVR due to misconceptions regarding their surgical risk and potential complications [2] . The late referral of these patients places them at a higher risk for perioperative complications and mortality from what otherwise would have been a much safer procedure.
Overall 30-day operative mortality for AVR patients is reported to be <4% [4, 5] , while 30-day mortality for high-risk patients can reach 8-12% [6] . Complication rates for AVR are also low, and patients can expect positive outcomes after undergoing this procedure. Nevertheless, the risk of undergoing AVR increases with certain factors, such as age, heart failure, renal failure or stroke [2, 7, 8] . Due to the concurrent presentation of coronary and valvular disease, a greater number of patients undergo concomitant coronary artery bypass (CABG) surgery at the time of AVR [9] . A study reported lower in-hospital mortality rates for AVR patients with concomitant CABG when compared with isolated AVR [7] . AVR with CABG can be performed with the minimal operative risk and reduces the likelihood of future reoperations.
An important feature of AVR is the selection of the appropriate size and type of the valve used for replacement. The patientprosthesis mismatch (PPM) occurs when the effective orifice area of a prosthetic valve is too small relative to a person's body size, which can lead to an increased risk for cardiac events and mortality [10] [11] [12] . PPM is defined as a calculated effective orifice area index (EOAI) value of ≤0.85 cm 2 /m 2 [11] . While there is some disagreement as to the exact boundaries of severe, moderate and non-existent PPM, they are typically demarcated at <0.65, 0.65-0.85 and >0.85 cm 2 /m 2 , respectively [13] . Even though PPM can be potentially problematic, moderate PPM has been shown not to have a significant impact on short-term mortality, except in patients with a poor ejection fraction [10, 14] . Severe PPM is a significant predictor of short-term mortality, particularly when associated with the left ventricular dysfunction [11] .
The identification and assessment of perioperative factors that influence outcome and survival in AVR patients are paramount. We sought to evaluate which factors were significantly independent predictors of in-hospital and 30-day perioperative outcomes in a large contemporary series of consecutive AVR and AVR+CABG patients. We also introduce a new predictor of mortality and outcome risk for these patients by coupling PPM and New York Heart Association (NYHA) classification as an independent new variable. The goal of linking these two variables was to corroborate recent suggestions that combining PPM with NYHA class III and IV will identify a group of patients who may be at increased risk for a negative outcome.
MATERIALS AND METHODS

Patient population
This study includes all consecutive patients who underwent isolated AVR with or without concomitant coronary artery bypass grafting (CABG) as well as reoperations at The Valley-Columbia Heart Center between January 2006 and December 2010. Data were collected prospectively using standard elements and definitions from the Society of Thoracic Surgeons (STS) database. The local Institutional Review Board (IRB) approved this database, and informed consent was waived for this study.
A total of 509 consecutive patients who underwent isolated AVR or AVR+CABG were available for the inclusion in this study. More than half (n = 266, 52.3%) of these patients underwent AVR +CABG, while the remainder underwent isolated AVR (n = 243, 47.7%). First-time and redo operations were included in this group, as our preliminary analysis of outcomes comparing firsttime and redo operations (AVR ± CABG) demonstrated no significant difference between these groups. General preoperative baseline characteristics and perioperative outcomes are presented in Tables 1 and 2 .
To evaluate the effect of age on surgical outcome, patients were placed into one of the following four groups based on the age and procedure: Group 1: isolated AVR ≥80 years old (n = 88); Group 2: isolated AVR <80 years old (n = 155); Group 3: AVR+CABG ≥80 years old (n = 105); and Group 4: AVR+CABG <80 years old (n = 161).
The overall goals of this study were to determine which factors were significantly associated with in-hospital and 30-day perioperative outcomes after AVR and AVR+CABG patients. We created a new variable by combining PPM and decreased functional status as defined by NYHA class III-IV as a potential predictor of mortality in these patients and analysed its effect on multivariate analysis. Relevant information regarding valve types and sizes and PPM can be found in the Supplementary material available online. In-hospital to 30-day complications and mortality were documented using standard definitions provided by the STS data registry.
Surgical technique
Each patient underwent AVR with or without concomitant CABG. All procedures were performed with the following standard techniques: central cannulation, roller pumps, membrane oxygenators, appropriate filters, antegrade and retrograde cardioplegia and mild hypothermia by letting the temperature drift during the case. 
RESULTS
Observed in-hospital and 30-day mortality for AVR was 1.2% and for AVR+CABG was 1.9% (Table 2 ). Patients undergoing isolated AVR had lower rates of reoperation for bleeding, prolonged ventilation and atrial fibrillation. Rates of postoperative permanent stroke, renal failure and length of stay were similar between the AVR and AVR+CABG patients. Overall observed in-hospital and 30-day mortality was 1.6% (n = 8). Seven of the eight deaths were due to cardiopulmonary causes, while the remaining was due to infection. The effect of age greater than or less than 80 was evaluated for AVR and AVR+CABG patients. In our series, patients younger than 80 years of age were more likely to be male, while the opposite was true for those older than 80 years. Younger AVR +CABG patients were also more likely to have diabetes mellitus than their older counterparts, while the same did not apply for isolated AVR patients (Table 3) .
The observed mortality rates of AVR and AVR+CABG patients grouped by age above and below 80 were compared to the STS predicted risk of mortality for each of these groups (Table 3) . STS-predicted mortality rates were significantly higher for patients over 80 years of age regardless of the procedure, while actual observed mortality rates were not significantly different between patients above and below 80 years of age.
In the overall patient cohort, univariate analysis demonstrated that NYHA class III-IV, intraoperative blood use and depressed left ventricular ejection fraction (LVEF<35%) were significantly associated with in-hospital to 30-day mortality (P < 0.05). This finding was not significant in the AVR or AVR+CABG subgroups. Moreover, increased ventilation hours for all subgroups of patients based on the age and procedure was associated with an increased risk of in-hospital to 30-day mortality (P < 0.05).
When the patient group was subdivided by the age and procedure, univariate analysis showed that AVR+CABG patients under the age of 80 with NYHA class III-IV were more likely to die in the hospital and/or within 30 days (P < 0.05). Univariate analysis also demonstrated that PPM and PPM+NYHA class III-IV were associated with in-hospital to 30-day mortality (Tables 4  and 5 ). Multivariate Cox proportional hazards regression analysis demonstrated that the presence of both PPM and NYHA class III-IV (adjusted OR = 16.173, P = 0.036) and reoperation (adjusted Note: Patients in the PPM + NYHA class III-IV (n = 49) are not double counted in the PPM only or NYHA class III-IV only groups. Indeed, about 10% of the PPM + NYHA class III-IV group of patients died in the hospital and within 30 days, when compared with the much lower amount of patients from either the PPM only group or the NYHA class III-IV group. OR = 18.815, P = 0.026) were significant predictors of in-hospital to 30-day mortality (Table 6 ).
DISCUSSION
Overall, our results of the short-term outcomes and mortality were favourable compared with those reported in previous studies [2, 7, 8, [15] [16] [17] [18] [19] . While PPM and NYHA class III-IV have been individually reported as significant predictors of the shortterm outcomes and mortality, we found that the combination of both PPM and NYHA class III-IV was an even more effective predictor of short-term mortality in patients undergoing AVR or AVR+CABG. This particular combination has not been analysed until now and represents a novel approach to evaluate outcomes in these patients. In our series, PPM+NYHA class III-IV and reoperation were shown to be the most effective predictors of short-term outcomes in AVR and AVR+CABG patients. However, NYHA class III-IV, PPM and age as separate variables were not shown to be significant predictors of short-term mortality, which contrasted with previous studies [20] . Since this study only looked at in-hospital to 30-day mortality and outcomes, information regarding the patients' functional status and quality of life after discharge was beyond the scope of this article and was not collected. After careful analysis, about 30% of the patients in our series had PPM (see Supplementary material). The majority of our PPM patients were characterized as having mild-to-moderate PPM (0.65-0.85 cm 2 /m 2 ) (Supplementary material). PPM is nonetheless preventable, and routine preoperative calculation of the EOAI value should become protocol. This would likely reduce the incidence of PPM and may improve short-term outcomes and survival, particularly for patients with advanced heart failure. Careful selection of the type of procedure (e.g. root enlargement + AVR versus AVR alone) and the selective use of specific valve designs (e.g. stented versus stentless) of aortic valve prostheses are some of the technical tools the cardiac surgeon can use to avoid PPM [11] , particularly in patients with advanced heart failure (NYHA class III-IV). In recent months, the introduction of new stentless aortic bioprostheses at our institution has helped us decrease the percentage of PPM in our AVR population. In order to avoid complications, the choice between these different techniques should reside in the hands of the surgeon depending on his/her level of comfort with each procedure and each particular bioprosthesis.
Both the Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) and European Score for Cardiac Operative Risk Evaluation (EuroSCORE) [21, 22] models are used for risk assessment for these procedures and incorporate numerous components. However, there are weaknesses to both. Most notably, both models tend to overestimate predicted mortality, particularly for high-risk patients. That was the case for our series, where the STS-predicted short-term mortality rates for our four different groups were higher than the actual mortality rates.
Several risk models have been developed to remedy the deficiencies and potentially supplement the predictive power of existing models such as the STS-PROM and EuroSCORE. Kuduvalli et al. [23] developed a multivariate model along with a simplified clinical risk assessment tool that assessed in-hospital mortality after AVR by incorporating a broader definition of With the advent of new and innovative treatments such as transcatheter aortic valve implantation (TAVI), existing risk stratification models require re-evaluation to better predict outcomes and mortality for patients who need valve replacements. TAVI can be used in patients who do not qualify for conventional AVR, because it is less invasive and provides superior valve haemodynamics [11] . If we are currently over-or underestimating the mortality risk of many of our elderly patients, we are artificially increasing the percentage of potential cases referred for TAVI when it is possible for those patients to safely undergo routine AVR with or without concomitant CABG.
Until these, new treatments are further refined and shown to be clinically effective, the benefits and low surgical risk support early referral of patients for AVR with concomitant CABG if needed, regardless of the age. Current guidelines recommend surgery for symptomatic AS patients but not necessarily for asymptomatic patients [25] . AVR has been shown to deliver promising results in terms of better outcomes and minimal mortality for asymptomatic and early risk patients [25] . Careful operative planning to prevent PPM should optimize outcomes and survival for patients undergoing AVR and AVR+CABG. By referring patients early for AVR, particularly the elderly, before the onset of symptoms and the development of advanced heart failure, we can effectively decrease their risk of complications and minimize their likelihood of being inoperable due to excessive risk.
Limitations
Key limitations of our study include its retrospective nature and the fact that the results represent a single institution's experience. Four surgeons with different techniques and preferences conducted these procedures. Moreover, the selection of the appropriate prosthesis for each patient was at the surgeon's discretion and was not standardized. All prostheses in our study were stented valves. The EOAI values were obtained from manufacturer-generated charts and do not necessarily correlate with postoperative or intraoperative EOAI measurements. Although used frequently by surgeons, EOAI charts are not approved by the Society of Thoracic Surgeons or the American Association for Thoracic Surgery and can be subjected to potential bias that favours the use of one prosthesis over another [1] . These charts should be used with caution.
Collectively, these various aspects may or may not have significantly contributed to the results found in this study. For example, if an institution predominantly serves a healthier and wealthier patient population and employs well-trained surgeons, it is likely that patient outcomes will be better than outcomes at another hospital that does not share the same characteristics. It is interesting to note that neither NYHA class III-IV nor PPM, as separate standalone variables, were significant predictors of short-term outcomes and mortality in our study, even though the combination of the aforementioned predictors was a significant predictor. It is quite possible that this observation can be attributed to the influence of the loss of statistical power in the results.
And lastly, we can acknowledge that while NYHA classification may not be the most specific or objective measure of cardiac performance, it is nonetheless important to investigate the predictive power of this variable in the context of AVR and AVR +CABG due to its widespread use, accuracy and convenience. We encourage further investigation on the predictive power and effects of the countless permutations of short-term and longterm predictors. These next steps can surely provide further clarification and refinement to existing risk models and algorithms to predict mortality and outcomes in AVR and AVR+CABG patients.
In conclusion, preventative measures like AVR to treat patients with AS before their condition deteriorates offer innumerable benefits. The challenge is to utilize the most accurate, precise and objective predictors and risk models to identify those patients who would benefit from such a procedure. Like any surgery, AVR has risks, but it remains the standard due to proven clinical success and relatively low rates of complications.
